Robot-assisted pyeloplasty: outcomes for primary and secondary repairs, a single institution experience

Matthew R. Thom
Washington University School of Medicine in St. Louis

Mohammed Haseebuddin
Washington University School of Medicine in St. Louis

Timur M. Roytman
Washington University School of Medicine in St. Louis

Brian M. Benway
Washington University School of Medicine in St. Louis

Sam B. Bhayani
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
http://digitalcommons.wustl.edu/open_access_pubs/5122

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Authors
Matthew R. Thom, Mohammed Haseebuddin, Timur M. Roytman, Brian M. Benway, Sam B. Bhayani, and Robert S. Figenshau

This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/5122
Robot-assisted pyeloplasty: Outcomes for primary and secondary repairs, a single institution experience

Matthew R. Thom, Mohammed Haseebuddin, Timur M. Roytman, Brian M. Benway, Sam B. Bhayani, Robert S. Figenshau

Division of Urologic Surgery, Washington University in St Louis, USA

ABSTRACT

Introduction: Robotic Pyeloplasty (RAP) is a technique for management of ureteropelvic junction obstruction (UPJO).

Purpose: To report outcomes of RAP for primary and secondary (after failed primary treatment) UPJO.

Materials and Methods: Single institution data of adult RAP performed from 2007 to 2009 was collected retrospectively following approval by our IRB. Database analysis included patient age, race, pre and post-operative imaging studies and perioperative variables including operative time, blood loss, pain and complications.

Results: Fifty-five adult patients underwent RAP (26 left/29 right) for UPJO including 9 secondary procedures from 2007 to 2009. Average follow-up was 16 months (1-36). Mean age was 41 years (18-71) with an average BMI of 27 (17-42); 32 were female. Most patients were diagnosed with preoperative diuretic renal scintigraphy and the obstructed side demonstrated mean function of 41% and t1/2 of 70 minutes. Mean operative time was 194 minutes with average blood loss less than 100 mL. Mean hospital stay was 1.7 days with an average narcotic equivalent dose of 15 mg. RAP for secondary UPJO took longer with more blood loss and had a lower success rate. Failure was defined as the need of another procedure due to persistent pain and/or obstruction after diuretic renal imaging. One patient (2%) with primary UPJO failed and 2 patients (22%) with secondary UPJO failed. One major complication occurred.

Conclusion: RAP is a good option for the treatment of patients with UPJO. Reported series have established that endopyelotomy has inferior success rate for the treatment of primary UPJO which compromises the success of subsequent treatment as demonstrated in our higher failure rate with secondary UPJO repair.

INTRODUCTION

Ureteropelvic junction obstruction (UPJO) is a disease of the proximal ureter resulting from both congenital and acquired causes. Open pyeloplasty remains the comparative gold standard for treatment (1-3). As an attempt to decrease associated morbidity of an open procedure, less invasive endoscopic techniques such as endopyelotomy were developed, but long-term outcomes were not as good as expected (4-6). Success of laparoscopic pyeloplasty is equivalent (7,8); however, due to its technical complexity, many urologists still perform a significant number of open and endoscopic
IBJU | ROBOT-ASSISTED PYELOPLASTY

procedures (9). This trend is rapidly changing as more surgeons become familiar with laparoscopic techniques and the rapid advancement of the robotic platform has eased the transition of the open surgeon into the era of minimally invasive surgery. We report our institutional outcomes of robotic-assisted pyeloplasty (RAP) for primary and secondary UPJO with the goal of contributing further evidence supporting RAP for primary UPJO repair.

MATERIALS AND METHODS

Medical records were retrospectively reviewed on all patients treated with RAP for UPJO at our institution from 2007 to 2009. Patient age, race, UPJO characteristics including pre-operative imaging, operative statistics (time, blood loss, complication), and post-operative follow-up information were recorded. Differentiation between primary and secondary repairs was made and included in final analysis. All patients were identified as having UPJO based on presenting symptoms and renal imaging, most often with nuclear diuretic renal scan (40 patients, 72%). UPJO was defined as clinically significant when obstructive hydronephrosis with diuretic renal scan was demonstrated t1/2 > 20 minutes. Renal anatomy, size of hydronephrosis and presence of crossing vessels was evaluated with contrasted CT imaging. Pre-operative ureteral stenting or nephrostomy tube placement was not routinely performed unless for specific clinical reasons such as pain control.

All procedures were performed by 2 experienced laparoscopic (RSF, SBB) surgeons using Intuitive Surgical DaVinci S/Si system®. A standard 3-arm technique was used with an additional assistant port. All procedures were performed transperitoneally. Dismembered pyeloplasty was performed in all cases with transposition of crossing vessels when present. Ureteral stent, typically positioned antegrade via the assistant port, was placed and confirmed in correct location with post-operative plain abdominal radiograph. Continuous bladder drainage via Foley catheter was maintained for 24-48 hours. Post-operative pain was managed with a combination of intravenous Ketorolac, narcotics and transitioned to oral medications once diet was advanced. Surgical drains, when placed, were removed prior to discharge unless high outputs were observed and/or fluid creatitine levels were greater than serum. Ureteral stents were removed after 3 weeks. Follow-up diuretic renal imaging was typically performed at 8 weeks.

RESULTS

55 adult patients underwent RAP (26 left/29 right) for UPJO including 9 secondary procedures from 2007 to 2009. Table-1 displays the cohort demographics. Average follow up was 16 months (1-36). Mean age was 41 years (18-71) with an average BMI of 27 (17-42); 32 were female. Most cases were diagnosed with preoperative diuretic renal scan (40 patients, 72%) with obstructed side demonstrating mean function of 41% and t1/2 of 70 minutes (Table-2). Mean operative time was 194 minutes with average blood loss less than 100 mL. Mean hospital stay was 1.7 days with an average narcotic equivalent dose of 15 mg. On average, RAP for secondary UPJO took longer with more blood loss and had a lower success rate (Table-3). Failure was defined as the need of another procedure due to persistent pain and/or obstruction on follow-up diuretic renal imaging. One patient (2%) with primary UPJO failed and 2 patients (22%) with secondary UPJO failed. One operative complication occurred secondary to trocar injury of the liver, requiring conversion to

<table>
<thead>
<tr>
<th>Table 1 - Patient Characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total renal units (side)</td>
</tr>
<tr>
<td>Age, mean (range)</td>
</tr>
<tr>
<td>Male/Female</td>
</tr>
<tr>
<td>Follow-up, mean (range)</td>
</tr>
<tr>
<td>BMI, mean (range)</td>
</tr>
<tr>
<td>Primary UPJO</td>
</tr>
<tr>
<td>Recurrent (secondary) UPJO</td>
</tr>
</tbody>
</table>
T ½, minutes 70 (20-376) 
Function, % 41 (14-50) 
Operative time, minutes 194 (112-433) 
Estimated blood loss, milliliters 95 (25-800) 
Hospital stay, days 1.7 (1-3) 
Narcotic use, morphine equivalents 15 (8-40)
review by Yanke et al. (16) evaluating RAP, retrograde endopyelotomy and laparoscopic pyeloplasty with a mean follow-up of 20 months showed a success rate of 60.2% of the retrograde endopyelotomy group, 88.2% for laparoscopic pyeloplasty, and 100% for RAP. Recurrence free survival for endopyelotomy was 50% at 7 years compared with 76% for laparoscopic pyeloplasty. Follow-up for RAP is currently in the beginning, however, it is assumed that RAP will likely mimic or may be better than the success rate of laparoscopic pyeloplasty over long-term. A retrospective review from Mayo Clinic (17) comparing antegrade endopyelotomy and pyeloplasty also showed similar findings. Endopyelotomy was found to be significantly inferior to pyeloplasty after 3, 5, and 10 years. The presence of extrinsic obstruction such as a crossing vessel or high grade hydronephrosis does not affect the outcome of operative pyeloplasty performed laparoscopic or with robot assistance (18). However, endopyelotomy success rates decreases significantly in the presence of these variables (18,19). Therefore, while pyeloplasty may be universally applied, endopyelotomy can only be safely and efficaciously used in very limited scenarios and even then the overall success rates are not durable.

The primary purpose of this study is to report outcomes of RAP and endorse its role for treatment of primary UPJO. Operative time, blood loss and complication rates are similar to larger series in the literature (20). As for patient outcomes,

### Table 4 - Laparoscopic/Robotic series.

<table>
<thead>
<tr>
<th>Study</th>
<th># patients</th>
<th>Lap/RAP</th>
<th>OR time</th>
<th>Hospital stay</th>
<th>Success</th>
<th>Complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inagaki et al. (13)</td>
<td>147</td>
<td>Lap</td>
<td>246</td>
<td>3.1</td>
<td>95%</td>
<td>8.8%</td>
</tr>
<tr>
<td>Romero et al. (29)</td>
<td>170</td>
<td>Lap</td>
<td>175.9</td>
<td>2.7</td>
<td>94.1%</td>
<td>7.7%</td>
</tr>
<tr>
<td>Moon et al. (30)</td>
<td>170</td>
<td>Lap</td>
<td>140</td>
<td>2.7</td>
<td>96.1%</td>
<td>7.1%</td>
</tr>
<tr>
<td>Rassweiler et al. (18)</td>
<td>143</td>
<td>Lap</td>
<td>125</td>
<td>5</td>
<td>94.4%</td>
<td>6.3%</td>
</tr>
<tr>
<td>Symons et al. (31)</td>
<td>118</td>
<td>Lap</td>
<td>205.4</td>
<td>4.7</td>
<td>94.5%</td>
<td>11.9%</td>
</tr>
<tr>
<td>Schwenter et al. (22)</td>
<td>92</td>
<td>RAP</td>
<td>108.3</td>
<td>4.6</td>
<td>96.7%</td>
<td>3%</td>
</tr>
<tr>
<td>Mufarrij et al. (21)</td>
<td>140</td>
<td>RAP</td>
<td>217</td>
<td>2.1</td>
<td>95.7%</td>
<td>11%</td>
</tr>
<tr>
<td>Current study</td>
<td>55</td>
<td>RAP</td>
<td>194</td>
<td>1.7</td>
<td>95%</td>
<td>2.5%</td>
</tr>
</tbody>
</table>

### Table 5 - Endopyelotomy series.

<table>
<thead>
<tr>
<th>Study</th>
<th># patients</th>
<th>Success</th>
<th>3/5/10 year</th>
<th>Complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knudsen et al. (32)</td>
<td>80</td>
<td>67%</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Ost et al. (19)</td>
<td>50</td>
<td>84%</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Dimarco et al. (17)</td>
<td>225</td>
<td>61%</td>
<td>63/55/41</td>
<td>11.1%</td>
</tr>
<tr>
<td>Szydelko et al. (33)</td>
<td>74</td>
<td>55.4%</td>
<td>---</td>
<td>22.5%</td>
</tr>
<tr>
<td>Rassweiler et al. (18)</td>
<td>113</td>
<td>77.6%</td>
<td>---</td>
<td>5.3%</td>
</tr>
</tbody>
</table>
while our overall success rate for primary UPJO are representative of what is reported in literature, our success rate for secondary UPJO is not. The overall success rate for our cohort is 95%; 98% for primary and 78% for secondary UPJO. Most of the RAP series indicate an overall success rate between 89-100% (20). Muffarrij et al. reported an overall success rate of 95.7% (96.6% in primary, and 91.3% in the secondary) (21). Similar results were observed in the series by Schwenter (22). Although many studies do indicate the high overall success rates, not many studies report the success rate for RAP in secondary UPJO, and none analyze these systematically. However, those that report them do indicate a trend towards a decrease in success rates in the secondary UPJO. Our low success rate in secondary UPJO could also be due to low sample size.

Endopyelotomy is an inferior treatment for the vast majority of primary UPJO due to lower success rates and consequently will compromise the success of subsequent treatments. Endoscopic management can be useful as a secondary procedure following pyeloplasty as multiple retrospective studies have demonstrated some success. Hoenig et al. demonstrated that endopyelotomy after failed open pyeloplasty was successful in 71% of cases. However, following primary endopyelotomy, endoscopic salvage is unlikely to relieve obstruction with success rate of 37.5% (23). Open repair for secondary obstruction demonstrates greater success with rates reported as high as 95% (24). As for laparoscopic pyeloplasty for secondary UPJJ obstruction after failed endopyelotomy, Sundaram reported an overall success rate of 83% with higher complication rate and longer operative time (25). This is similar to our outcomes for secondary repairs. Overall, laparoscopic pyeloplasty/RAP for secondary UPJO after failed endopyelotomy shows a poor overall success rate, increased complication rate, and increased operating time.

RAP is minimally invasive with a decreased length of hospitalization and faster convalescence as compared to open pyeloplasty. While laparoscopic pyeloplasty is an excellent alternative to open surgery, the drawback is a steep learning curve, and the difficulty with intracor-poreal suturing (26). This limitation precludes its widespread use. In a contemporary survey study looking at current practice patterns of primary UPJO, 78% of urologists in community practice stated they prefer an open approach while 67% of academic urologists stated that they prefer a laparoscopic approach (27). RAP has a potentially shorter learning curve (28) and may enable laparoscopic-naive urologist to perform the procedure easily, bridging the gap between academic and community urologists. Therefore, we endorse RAP as the procedure of choice for primary UJJP reserving endopyelotomy for secondary procedures.

CONCLUSIONS

RAP is a good option for the treatment of patients with primary UPJO. Reported series have established that endopyelotomy has an inferior success rate for the treatment of primary UPJO which compromises the success of subsequent treatment as demonstrated by our higher failure rate with secondary UPJO repair.

ABBREVIATIONS

RAP: Robot-assisted pyeloplasty
UPJO: Ureteropelvic junction obstruction

ACKNOWLEDGEMENTS

Cathy Chen, RN for assistance with data collection.
This project was funded in part by a grant from Midwest Stone Institute

CONFLICT OF INTEREST

Matthew Thom - None
Mohammed Haseebuddin - None
Timur M Roytman - None
Brian M Benway - Consultant, Viking systems
Sam B Bhayani - Consultant, Intuitive Surgical
Robert S Figenshau - None
REFERENCES


Correspondence address:
Dr. Sherb Figenshau
Division of Urologic Surgery
Taylor Family - Ralph V. Clayman, M.D.
Division of Urology
Washington University School of Medicine
Telephone: + 1 314 454-2235
E-mail: figenshaur@wustl.edu